Welcome to our dedicated page for CIBUS SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cibus, Inc. (Nasdaq: CBUS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Cibus’ operations as an agricultural technology company that develops and licenses gene-edited plant traits to seed companies.
Through its recent Forms 8-K, Cibus has reported a range of material events, such as quarterly financial results and business updates, workforce reduction decisions, and the appointment of key executives and directors. For example, filings describe the appointment of a Chief Financial Officer under an executive employment agreement, the election of new board members with experience in technology, agriculture and finance, and actions to streamline the business by consolidating facilities and reducing headcount.
These filings also confirm that Cibus’ Class A common stock, with par value $0.0001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the symbol CBUS. Investors reviewing the filings can see how the company describes its focus on productivity traits for major row crops, its reliance on licensing and royalty arrangements, and its assessment of risks and strategic alternatives as referenced in its periodic reports.
On Stock Titan, Cibus filings are supplemented with AI-powered summaries that help explain the key points of lengthy documents, such as current reports on Form 8-K or sections of annual and quarterly reports. Users can quickly identify items related to executive changes, cost structure adjustments, or updates to trait development programs, and then drill down into the full text for more detail. Real-time updates from EDGAR, combined with AI-generated highlights, make it easier to track CBUS regulatory disclosures, including insider-related items reported on Form 4 and the narrative and risk discussions contained in Forms 10-K and 10-Q.
Cibus, Inc. entered into an underwriting agreement with BTIG, LLC for a public offering of 13,333,333 shares of Class A common stock at $1.50 per share. The company expects net proceeds of about $17.8 million, or $20.5 million if BTIG exercises its 30-day option to buy up to 1,999,999 additional shares.
Members of the board of directors will purchase 1,000,000 shares at the offering price, and directors, executive officers and the company agreed to a 60-day lock-up on additional sales, subject to limited exceptions. BTIG will receive a 6.25% underwriting discount and reimbursement of documented expenses up to $150,000. The deal is expected to close on or about January 30, 2026, subject to customary conditions.
Cibus, Inc. is conducting a primary underwritten offering of 13,333,333 shares of Class A common stock at $1.50 per share, with gross proceeds of about $20.0 million and estimated net proceeds of approximately $17.8 million before any exercise of the underwriter’s option for 1,999,999 additional shares.
The company plans to use the cash mainly for working capital and general corporate purposes, including further development of its weed management traits in Rice and payment of accrued advisory fees, including about $2.4 million owed to Ducera. Members of the board are purchasing 999,999 shares at the public price, and CBUS remains listed on Nasdaq.
Cibus highlights significant dilution: its net tangible book value was $(4.04) per share as of September 30, 2025, and investors in this deal face immediate dilution of about $4.46 per share. The company had $23.9 million in cash and cash equivalents and $20.6 million in current liabilities as of that date, is targeting annual net cash usage of roughly $30 million in 2026, and warns that it still needs additional financing and could ultimately be forced to wind down through bankruptcy, potentially leaving shareholders with little or no recovery.
Cibus, Inc. filed an update describing its business focus and cost-cutting steps made alongside an underwritten offering. The agricultural biotechnology company develops gene-edited plant traits it licenses to seed companies for per‑acre royalties, targeting productivity, sustainability, and yield improvements.
The company is prioritizing herbicide-tolerant weed management traits for Rice, estimating potential annual accessible royalties of over $200 million in Latin America and the United States, and additional royalty opportunities in Asia and India. Management’s longer-term goal is to address about 200 million of the roughly 400 million global rice acres.
Cibus is also advancing sustainable ingredients programs, including a yeast fermentation biofragrance line that management believes could generate $20–40 million in annual revenue over time. Through 2025 it streamlined operations, including a workforce reduction completed by December 31, 2025, and expects these actions to reduce annual net cash usage to about $30 million or less during 2026 while it consolidates core operations in San Diego and concentrates spending on Rice programs.
Cibus, Inc. plans an underwritten public offering of Class A common stock on Nasdaq to raise cash for operations and its rice weed-management trait programs. Board members may buy up to approximately $1.5 million of shares at the public price, and BTIG is the sole bookrunner with a 30‑day option to purchase additional shares.
Cibus highlights significant going concern risks. As of September 30, 2025, it held $23.9 million in cash and cash equivalents against $20.6 million in current liabilities, and it is targeting annual net cash usage of about $30 million or less during 2026 after restructuring and workforce reductions.
The company is focusing capital on herbicide-tolerant rice traits, which management believes could ultimately support annual accessible royalties of over $200 million in initial markets, while pursuing partner-funded programs in biofragrances and lauric oils. A special board committee is exploring strategic alternatives, including financings, business combinations, asset sales and licensing, and warns that failure to secure sufficient capital could lead to a wind-down in which shareholders may lose most or all of their investment.
Cibus, Inc. (CBUS) reported an equity award to a company director. On 11/05/2025, the director received a stock option to buy 45,627 shares of Class A common stock at an exercise price of $1.32 per share. The option becomes exercisable on 05/22/2026 and expires on 11/05/2035, with no purchase price paid for the option itself. Following this grant, the director beneficially owns 45,627 derivative securities directly.
The option vests, subject to continued board service, on the earlier of the first anniversary of the grant date or the company’s next annual shareholder meeting. Any remaining unvested portion will fully vest if a defined Triggering Event under the company’s 2017 Omnibus Incentive Plan occurs while the director continues to serve.
Cibus, Inc. filed an initial ownership report for director Craig Wichner. The Form 3 indicates that, as of the event date of 11/05/2025, he beneficially owns 0 shares of Cibus Class A Common Stock in direct form. The filing also shows no reportable derivative securities, meaning there are no listed options, warrants, or other convertible instruments tied to Cibus stock for this reporting person at this time.
Cibus, Inc. filed its Q3 2025 10‑Q, reporting continued operating losses and a going concern warning. Revenue was $615 thousand for the quarter and $2.6 million year‑to‑date, reflecting limited current commercialization. Quarterly net loss was $24.3 million; year‑to‑date net loss was $100.3 million.
Cash and cash equivalents were $23.9 million as of September 30, 2025, against $20.6 million in current liabilities. Management states that additional capital will be needed within a year to support plans. The company raised net proceeds of approximately $21.4 million in January 2025 and $25.0 million in June 2025 follow‑on offerings and terminated its prior ATM facility without 2025 sales.
Year‑to‑date operating expenses totaled $77.5 million, including a $20.9 million goodwill impairment recognized in Q1. A July workforce reduction of ~34 roles incurred $0.2 million in severance in Q3. As of November 10, 2025, the company reported 54,283,111 shares outstanding across Class A and Class B.
Cibus, Inc. reported its results for the three months ended September 30, 2025 and provided a year‑to‑date business update. The company furnished a press release with details as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed “filed” under the Exchange Act, limiting its use for liability purposes unless specifically incorporated by reference. The report was signed by Interim Chief Executive Officer Peter Beetham on November 13, 2025.
Cibus, Inc. (CBUS) appointed Craig Wichner to its Board of Directors, effective November 5, 2025, and named him to the Board’s Strategy Committee.
Wichner is the Founder and Managing Partner of Farmland LP, a U.S. farmland investment manager with more than $350 million in assets and over 19,000 acres under management. His annual director compensation includes a $60,000 cash retainer (payable semi-annually) and equity with a grant date value of $90,000, prorated for the remainder of fiscal 2025, subject to Board approval under the company’s 2017 Omnibus Incentive Plan. He also entered into the company’s standard indemnification agreement.
Kimberly A. Box, a director of Cibus, Inc. (CBUS), was granted a stock option on 09/11/2025 to purchase 54,722 shares of Class A common stock at an exercise price of $1.40 per share. The option vests on the earlier of the first anniversary of the grant date or the company’s next annual shareholders meeting, subject to continued service, and becomes exercisable beginning 09/11/2026 with an expiration date of 09/11/2035. The filing reports direct beneficial ownership of 54,722 shares following the grant. The grant includes standard acceleration on a defined Triggering Event per the company’s 2017 Omnibus Incentive Plan.